Paroxetine - Administration & dosage
Research News and Information

Saturday, November 21, 2009

The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.

5 Jul 2009 INTRODUCTION: Co-morbid medical and psychiatric conditions are common in individuals with schizophrenia. As such, selecting antipsychotic medications with a low potential for drug-drug interactions (DDIs) is crucial, as many are extensively ... Read more...

Antidepressant-like effects of paroxetine are produced by lower doses than those which produce nausea.

25 May 2009 Paroxetine is prescribed to treat depression, but it also produces nausea. The potential of animal models to detect nauseating, antidepressant-like, and rewarding/aversive effects of paroxetine were assessed. In Experiments 1 (spaced conditioning ... Read more...

A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study.

24 May 2009 BACKGROUND: Because a large proportion of patients with panic attacks receiving approved pharmacotherapy do not respond or respond poorly to medication, it is important to identify additional therapeutic strategies for the management of panic ... Read more...

Latest indexed articles for 'Paroxetine - Administration & dosage'

These are the very latest articles for this heading:

• Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder". 30 Jul 2009
• The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. 5 Jul 2009
• Antidepressant-like effects of paroxetine are produced by lower doses than those which produce nausea. 25 May 2009
• A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. 24 May 2009
• A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. 3 May 2009
• Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief. 21 Apr 2009
• High-dose paroxetine treatment for an adolescent with obsessive-compulsive disorder comorbid with Asperger's disorder. 30 Mar 2009
• Effects of antidepressants on GluR2 Q/R site-RNA editing in modified HeLa cell line. 23 Mar 2009
• The brain 5-HT4 receptor binding is down-regulated in the Flinders Sensitive Line depression model and in response to paroxetine administration. 21 Mar 2009
• Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations. 27 Feb 2009
• Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. 30 Jan 2009
• The risks and benefits of switching antipsychotics: a case study approach. 30 Dec 2008
• A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. 30 Dec 2008
• An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. 29 Nov 2008
• Clinical evaluation of paroxetine in post-traumatic stress disorder (PTSD): 52-week, non-comparative open-label study for clinical use experience. 29 Nov 2008
• An open-label, noncomparative, dose escalation pilot study of the effect of paroxetine in treatment of burning mouth syndrome. 6 Nov 2008
• Paroxetine: safety and tolerability issues. 30 Oct 2008
• Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. 16 Oct 2008
• Effects of intrathecal administration of newer antidepressants on mechanical allodynia in rat models of neuropathic pain. 13 Oct 2008
• Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial. 5 Oct 2008

See a longer list of these articles.

Technical information about 'Paroxetine'

Definition: A serotonin uptake inhibitor that is effective in the treatment of depression.

Chemical name: Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S-trans)-

Registry Number: 61869-08-7

Descriptor UI: D017374

Alternative terms: Paroxetine; Seroxat; FG-7051; Aropax; BRL-29060; BRL 29060; BRL29060; Paroxetine, trans-(+)-Isomer; Paroxetine Hydrochloride; Hydrochloride, Paroxetine; Paroxetine Hydrochloride, Hemihydrate; Hemihydrate Paroxetine Hydrochloride; Hydrochloride, Hemihydrate Paroxetine; Paroxetine Maleate; Maleate, Paroxetine; Paroxetine, cis-(+)-Isomer; Paroxetine, cis-(-)-Isomer; Paxil; Paroxetine Acetate; Acetate, Paroxetine;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Serotonin Uptake Inhibitors; Antidepressive Agents, Second-Generation;

Tree Number: D03.383.621.600;

Online Note: use PAROXETINE (NM) to search PAROXETINE 1980-92

History Note: 93; was PAROXETINE (NM) 1978-92